Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Question on interview

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 24, 2022 5:10pm

220 Views

Post# 35126371

RE:Question on interview

Doccole wrote: Dan reported that Antibe never saw the elevated liver enzymes in the animal studies and it wasn't until after it was discovered.

how does this new formation and new tests in animal studies rule out or support a reduced potency and lower enzymes?

First - the acute trial is only 5 days (as per Dan).
2nd - dosing will be 2-4 fold less than we had.
Liver enzyme is not an issue for acute.

Also - 5 days is self-limiting and after 5 days, it's self-repairing.

Wins all around.

Risk has moved elsewhere.

--------------------

Different story on the chronic side with 3 potential ways to market (as I see it).

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide